|
Product Press Releases
2009 2008 2007 2006 2005 
Search ReleasesSeptember Wednesday, Sep 16, 2009 Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance July Thursday, Jul 02, 2009 Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion May Tuesday, May 05, 2009 FDA Grants Accelerated Approval of Avastin for Brain Cancer (Glioblastoma) That Has Progressed Following Prior Therapy April Tuesday, Apr 21, 2009 Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint Wednesday, Apr 08, 2009 Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. Market March Tuesday, Mar 31, 2009 FDA Advisory Committee Unanimously Recommends Accelerated Approval of Avastin for Previously Treated Brain Cancer (Glioblastoma) Wednesday, Mar 18, 2009 OSI Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Tarceva as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Wednesday, Mar 11, 2009 Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint February Monday, Feb 02, 2009 Phase III Study Showed Tarceva in Combination With Avastin as First-Line Maintenance Therapy Improved Progression-Free Survival in Advanced Lung Cancer
 |
